Elanco Animal Health Incorporated (NYSE:ELAN) Receives Average Recommendation of “Hold” from Brokerages

Elanco Animal Health Incorporated (NYSE:ELAN) has been given an average rating of “Hold” by the eight brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $16.29.

ELAN has been the topic of several recent analyst reports. Leerink Partnrs raised Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. Morgan Stanley decreased their target price on shares of Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 29th. Leerink Partners initiated coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price target for the company. UBS Group assumed coverage on shares of Elanco Animal Health in a report on Monday, December 9th. They issued a “buy” rating and a $18.00 price objective on the stock. Finally, Stifel Nicolaus lowered their price objective on shares of Elanco Animal Health from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th.

Hedge Funds Weigh In On Elanco Animal Health

A number of hedge funds have recently modified their holdings of ELAN. JPMorgan Chase & Co. raised its holdings in shares of Elanco Animal Health by 76.6% in the third quarter. JPMorgan Chase & Co. now owns 10,057,656 shares of the company’s stock valued at $147,747,000 after buying an additional 4,361,799 shares during the last quarter. State Street Corp raised its stake in Elanco Animal Health by 2.6% during the 3rd quarter. State Street Corp now owns 9,912,693 shares of the company’s stock valued at $145,617,000 after acquiring an additional 255,084 shares during the last quarter. Geode Capital Management LLC lifted its position in Elanco Animal Health by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company’s stock worth $115,623,000 after acquiring an additional 65,303 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Elanco Animal Health by 6.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 6,385,467 shares of the company’s stock valued at $93,803,000 after purchasing an additional 394,921 shares during the last quarter. Finally, Brandes Investment Partners LP increased its holdings in shares of Elanco Animal Health by 66.9% in the fourth quarter. Brandes Investment Partners LP now owns 5,731,180 shares of the company’s stock valued at $69,405,000 after purchasing an additional 2,296,691 shares during the period. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Stock Down 0.5 %

ELAN stock opened at $11.47 on Tuesday. The firm has a market cap of $5.67 billion, a PE ratio of 28.67, a PEG ratio of 2.69 and a beta of 1.42. Elanco Animal Health has a one year low of $11.11 and a one year high of $18.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The firm’s 50 day moving average price is $12.01 and its 200-day moving average price is $13.19.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.